DoD Traumatic Brain Injury and Psychological Health, Investigator Initiated Research Award | W81XWH 22 TBIPHRP IIRA

Opportunity Information: Apply for W81XWH 22 TBIPHRP IIRA

The DoD Traumatic Brain Injury and Psychological Health, Investigator Initiated Research Award (FY22 TBIPHRP IIRA; Funding Opportunity Number W81XWH-22-TBIPHRP-IIRA) is a Department of Defense funding opportunity managed through the U.S. Army Medical Research Acquisition Activity (USAMRAA). Its purpose is to support investigator-driven studies that make a meaningful contribution to understanding, preventing, assessing, or treating traumatic brain injury (TBI) and/or psychological health conditions. The program is designed to move the field forward in ways that matter to real-world patient care and operational needs, especially within the focus area(s) identified by the FY22 TBIPHRP, and it expects applicants to explain clearly why their proposed work addresses an important unanswered question or pressing problem.

A key feature of this award is its broad allowance for the type and stage of research, as long as the project is not a clinical trial. Proposed work can span basic laboratory studies, translational research, and preclinical efforts, including animal model studies and human subjects research. The announcement also allows correlative studies that are connected to an existing clinical trial, meaning applicants can analyze samples or data associated with a trial that is already underway, as long as the IIRA funds are not used to run the trial itself or prospectively assign people to interventions. In other words, the mechanism supports discovery and translation and can involve humans and human-derived materials, but it draws a firm line at using this particular award to conduct interventional clinical trials.

The opportunity is very explicit about what counts as a clinical trial and why that matters for eligibility. A clinical trial is defined here as a research study where one or more human subjects are prospectively assigned to one or more interventions (including placebo or control conditions) to evaluate the effects on biomedical or behavioral health-related outcomes. Projects that meet that definition are not allowed under this award. The funding announcement also prohibits studies requiring an exception from informed consent (EFIC). If an applicant wants to propose a clinical trial, the DoD directs them instead to other FY22 TBIPHRP mechanisms specifically intended for trials or more trial-like translational efforts, including the Clinical Trial Award (W81XWH-22-S-TBIPH1), Focused Program Award (W81XWH-22-S-TBIPH2), Translational Research Award (W81XWH-22-TBIPHRP-TRA), and Patient-Centered Research Award (W81XWH-22-TBIPHRP-PCRA).

The notice also clarifies the broader concept of clinical research, which can include patient-oriented research involving direct interaction with human subjects (or identifiable human-origin materials), epidemiologic and behavioral studies, and outcomes or health services research. Importantly, not all human-related work is treated the same: studies that qualify for Institutional Review Board (IRB) Exemption 4 (work using existing, de-identified specimens or data that are publicly available) are not considered “CDMRP-defined clinical research” under this framework. Applicants are encouraged to use the program’s human subject guidance documents to avoid misclassification, since whether a study is a clinical trial versus non-trial clinical research can determine if it is eligible for this award.

For applicants proposing animal work, the program signals a preference for models that are tightly linked to clinical reality. The announcement encourages pairing clinical populations with animal models when possible, to help validate that the model reflects human TBI or psychological health conditions and to support development of prevention, assessment, and treatment solutions that have a credible path to impact. It also emphasizes that animal models must be well-justified, grounded in the literature, and clearly aligned with clinical relevance rather than being exploratory models with weak ties to human disease or recovery.

Another core requirement is that preliminary data are mandatory. Applicants must provide relevant evidence supporting both the rationale and the feasibility of the proposed study. The program allows preliminary support to come from different sources, including laboratory discoveries, population-based findings, clinical experience, or even anecdotal observations, but it still expects the application to include concrete data that make the proposal believable and actionable. Unpublished preliminary data can be used, but the announcement specifies that such unpublished data should originate from the PI’s lab or from members of the research team, reinforcing that the group proposing the work should already have a foundation demonstrating capability and readiness.

From an administrative standpoint, this is a discretionary DoD research opportunity under CFDA 12.420, using grant and/or cooperative agreement instruments. Eligibility is described as unrestricted (open to any entity type, subject to any additional eligibility clarifications in the full announcement). The opportunity was posted July 15, 2022, with an original closing date of September 14, 2022, and anticipated making around 17 awards. The listed award ceiling is shown as 0 in the summary field, which typically means applicants must consult the full funding announcement for detailed budget limits or that limits vary by proposal scope and are not expressed as a single cap in the synopsis.

Overall, the IIRA is best viewed as a flexible research mechanism for well-supported, hypothesis-driven or solution-oriented projects in TBI and psychological health that can credibly lead to near-term deliverables (such as validated biomarkers, improved assessment tools, mechanistic insight, or preclinical proof-of-concept data) and longer-term outcomes (like clinically relevant interventions, diagnostics, or care strategies). The program’s central expectations are a clear connection to TBIPHRP focus areas, strong justification and preliminary evidence, and a persuasive explanation of how the work could ultimately improve understanding and care without crossing into running a clinical trial under this specific award.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Traumatic Brain Injury and Psychological Health, Investigator Initiated Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jul 15, 2022.
• Applicants must submit their applications by Sep 14, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 17 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 TBIPHRP IIRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: